Shares in Valeritas (NSDQ:VLRX) are down more than 15% in after-hours trading despite the medtech firm releasing first quarter 2019 earnings that beat sales expectations and met loss-per-share consensus from Wall Street analysts.
The Bridgewater, N.J.-based company posted losses of approximately $14.7 million, or 15¢ per share, on sales of $6.4 million for the three months ended March 31, seeing losses grow 26.9% while sales grew 5.3% when compared to the same period during the previous year.
Read the whole story on our sister site, Drug Delivery Business News
